Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 21.99 |
---|---|
High | 21.99 |
Low | 21.99 |
Bid | 21.87 |
Offer | 22.08 |
Previous close | 21.99 |
Average volume | -- |
---|---|
Shares outstanding | 55.22m |
Free float | 52.45m |
P/E (TTM) | 33.82 |
Market cap | 1.99bn USD |
EPS (TTM) | 1.07 USD |
Data delayed at least 15 minutes, as of Dec 29 2020.
More ▼
Announcements
- Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
- Supernus Announces Third Quarter 2024 Financial Results
- Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
- Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
- Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
- Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
- Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
- Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
- Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
- Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
More ▼